Clinical Trial Update: OPAL - Insulin Glulisine, Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial update for insulin glulisine in type 2 diabetes indicates the study has completed; no efficacy or safety results are provided in the summary.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus Type 2 | Phase 3 | Status: COMPLETED